Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several li...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-01-01
|
| Series: | Annals of Oncology Research and Therapy |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/aort.aort_30_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several lines of treatment is an often-encountered clinical scenario, here we would like to highlight the use of Daratumumab a novel anti CD 38 monoclonal antibody to treat post-transplant AIC. We report on the use of Daratumumab in combination with the conventional treatment with Rituximab and corticosteroids in a case of severe life threatening AIHA in a one-year-old child, who was suffering from T-B-NK SCID, and had undergone post haploidentical stem cell transplantation. |
|---|---|
| ISSN: | 2772-8382 2772-8390 |